China’s Biopharma Sector Facing Internal And External Woes
This article was originally published in PharmAsia News
Executive Summary
China’s biopharma sector continues to be plagued by a host of issues including fragmented development, outdated technology, financing difficulties, long approval timelines, insufficient intellectual property rights protection and talent shortages.